WHO Resumed Approval Process for Sputnik V

The World Health Organization (WHO) has resumed the approval process for Russia’s Sputnik V COVID-19 vaccine, as reported by the Russian Direct Investment Fund (RDIF).  

The WHO press service told on September 27 that it was waiting for additional information about Sputnik V from Moscow and only after this data was considered it would be possible to organize an inspection trip to Russia by international experts. In early October, the WHO said that the listing process for the Russian jab was “put on hold,” but will be “sorted out quite soon.”

Now, as the RDIF CEO, Kirill Dmitriev, mentioned in his interview with CNN, WHO experts were expected in Russia soon, so he was hopeful Sputnik V would be approved by the WHO within the next two months. Currently, the world’s first registered COVID-19 vaccine, Sputnik V, with over 91.6 per cent efficacy is authorised for use in 70 countries.

In addition to this piece of good news, another interesting study has appeared in scientific circles, Sputnik reports. A group of US scientists pitted several COVID-19 vaccines against each other, with human adenovirus vector jabs outperforming mRNA shots. Such findings are also backed by Argentinian scientists, who explored long-term data.

As noted by the scientists, mRNA vaccines provide a high peak antibody response against COVID-19 but lose most of their efficacy within 6 months, while human adenoviral vector vaccines provide stable protection levels within 8 months after vaccination.

The results of the American research were echoed by another recent study from Argentina. Argentinian scientists have concluded that Sputnik V, which is based on a human adenoviral vector, provides antibody “maturation” and increased protection against the coronavirus within a 6-month period.

It is stated that the Pfizer and Moderna vaccines are based on experimental mRNA technology that hasn’t been used extensively prior to the COVID-19 pandemic, while Janssen (Johnson & Johnson) and Sputnik V rely on well-known human adenovirus vector carrier technology, where genetic coding for the desired antigen is delivered via a non-replicating virus vector.

Both Johnson & Johnson and Sputnik V employ the human adenoviral vector Ad26, but Sputnik V also has a safeguard in the form of a heterologous prime-boost method, thus, if a person has previously been exposed to Ad26 and this component fails to work effectively as a result, the second of the two Sputnik V jabs is designed to bypass this drawback with the use of a different adenoviral platform – Ad5.

Finally, while Sputnik V uses the human adenoviral platform, AstraZeneca’s jab is based on a chimpanzee adenovirus. So, as we see, the Russian vaccine shows the highest efficacy, protection, and reliability among all the others.

Ru-Main, 21.10.2021
Source: TASS

Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *